The Veeva Pulse Field Trends Report for the second quarter of 2025, built on over 600 million HCP interactions collected from more than 80% of global biopharma field teams, contains a weighty data point: content-driven engagement more than doubles treatment adoption, but content is actually used in fewer than half of HCP meetings. It is the most visible symptom of a structural dysfunction: pharma content production grew 7% globally and 29% in the United States in 2023, but 77% of approved content is almost never used by the sales network. Reuters Events Pharma estimates around $20 billion per year of pharma spending on content that HCPs will never see.
Closed-loop marketing had been designed precisely for this: to measure what the HCP sees during the visit, understand what works, feed back into subsequent planning. In practice the loop has broken at two points — the way content is produced (monolithic, long MLR cycles, poor reusability) and feedback closure (CRMs very good at recording visits, mediocre at linking them to content used and prescribing outcomes). Between October and December 2025 Veeva and Salesforce put into production native AI agents that attack both points simultaneously.
The loop that does not close
The Veeva Pulse snapshot on the global engagement mix in 2025 is 78% face-to-face and 22% digital, with a 7% year-on-year reduction in in-person HCP visits. Companies that have integrated inbound channels — HCP portals, reactive requests, on-demand content delivery — rebalance toward 42% F2F and 58% digital. It is a universe in which content should be the main engine, because digital by nature exposes the HCP to measurable materials: pages viewed, videos opened, links clicked, viewing duration. That data, however, rarely re-enters the subsequent planning cycle.
The measurable strength of synchronization between sales and marketing was quantified by Veeva in its 2024 survey: HCP engagement synchronized between the two functions produces a 60% increase in prescription rates compared to non-synchronized engagement. It is the single highest-return lever that pharmaceutical companies can activate on their CRM and content investments, and it remains significantly underused. McKinsey estimates that for pharma organizations that have reached omnichannel maturity there is a revenue increase between 5 and 10%, marketing efficiency between 10 and 20%, prescriber growth between 3 and 5% and HCP satisfaction increase between 5 and 10%. The difference between those who measure and those who don't, in this sector, has grown not narrowed.
The MLR bottleneck: 50-60 days per asset
Medical-Legal-Regulatory review of promotional content is the constraint that mechanically slows the loop. Vodori and Indegene 2024 surveys measure review cycles between 50 and 60 days per asset at large pharma, with a European average around 20 days and 1.3 revision cycles per asset. In parallel, the volume of content submitted to MLR has tripled over the last five years. The combination — growing volume, constant review duration — produces a compression effect that pushes commercial teams to produce generic reusable content, exactly the opposite of what closed-loop marketing would require.
The technical answer available since 2025 is the combination of content modularization and AI for review. Veeva's PromoMats 25R3 introduced in 2025 the agentic Quick Check, an automatic compliance check in the early phases of review. Indegene published a case study with a top-10 pharma in which AI deconstruction of existing content allowed tagging of over 200,000 pages in 30 countries and 18 languages, with an 85% reduction in tagging effort. BCG quantifies in its 2025 analysis a 30-50% reduction in content generation cost thanks to GenAI, with a documented case of 75% reduction in campaign launch time at a large pharma.
Veeva AI Agents and the iPad as agent
On December 3, 2025 Veeva made AI Agents for Vault CRM generally available. For closed-loop marketing the two relevant agents are the Pre-call Agent — which automatically reconstructs the HCP context including content previously viewed, engagement gaps and external signals — and the Media Agent, which enables conversational retrieval of approved promotional content. The declared technology stack is based on Anthropic and Amazon models hosted on Amazon Bedrock. X-Pages, the next generation of MyInsights, declares an average saving of about thirty minutes per day per medical representative and a satisfaction rate of 90%.
Salesforce made Life Sciences Cloud for Customer Engagement generally available on October 11, 2025 and rebranded it Agentforce Life Sciences. The functions relevant to CLM include Smart Summaries, Key Account Management, Intelligent Content and a journey orchestration system built on top of Marketing Cloud Next. Over seventy life sciences customers joined between October and the end of 2025, including Pfizer, Takeda, Boehringer Ingelheim and Fresenius Kabi. The architectural point is that both platforms have shifted closed-loop from the terrain of reporting to the terrain of the agent: the system no longer waits for the representative to record the visit in order to learn, it does so in real time and suggests the next step before the rep leaves the office.
The Italian constraint: the loop is digital, the value stays in the office
IQVIA data from November 2025 place Italy in first position in EU5 for share of sales impactable by face-to-face — 64% — and for alignment of channel mix with HCP-stated preferences, at 67%. The preference for F2F in Italy is 46% against 25% in the United Kingdom, and the preference for email grew to 14% in 2024 from 10% in 2023. It is a market in which closed-loop marketing cannot be designed as it is in the United States, where digital is dominant: in Italy the loop must be built around a F2F visit that remains the moment of maximum value transfer, with digital preparing its context before and consolidating its memory after.
The Italian regulatory constraint amplifies this asymmetry. The Farmindustria Code of Conduct, last revised February 21, 2025, requires the classification of every piece of content as promotional or non-promotional, the explicit consent of the HCP for promotional electronic communications and the complete audit trail of delivery. Sanità Trasparente, operational since 2025, requires public disclosure of transfers of value to HCPs above 100 euros per single event or 1,000 euros per year. An effective Italian closed-loop in 2026 is not the one that imports Veeva's or Salesforce's global blueprint: it is the one that translates its structure into local constraints, where the Italian system integrator works more than the license provides. The 77% of content that is not used is also 77% of investment that does not return. It is a margin worth more than the cost of the platform itself.
